How much has Colossal Biosciences raised?

Colossal Biosciences has $435 million reported as of january 2025 based on public reporting. 2021: Seed/Series A — $15 million, led/backed by Breyer Capital and others. 2022: Series A/B — $60 million, led/backed by Thomas Tull and investors. 2023: Series B — $150 million, led/backed by United States Innovative Technology Fund. 2025: Series C — $200 million, led/backed by TWG Global and investors ($10.2 billion valuation).

Where debt, secondaries, or preferred-equity packages are included in public reporting, they are described as reported rather than converted into common-equity funding.

The disclosed investor base includes Breyer Capital and others; Thomas Tull and investors; United States Innovative Technology Fund; TWG Global and investors. These investors matter because they indicate whether the company is optimized for venture-scale software growth, capital-intensive deployment, clinical development, or government procurement.

For sellers, investor quality is a useful signal, but procurement timing still depends on budget ownership and integration urgency.

The latest public marker is $10.2 billion reported after Series C. Valuation movement appears tied to progress in de-extinction biotechnology, public customer/partner proof, and the broader investor appetite for AI-enabled category leaders.

No public source confirms profitability, so valuation should be treated as a financing-market signal rather than an operating-margin signal.

Colossal Biosciences has not publicly disclosed audited profitability. IPO timing is not confirmed unless explicitly stated in company or news sources.

The practical read is that the company remains private and is using capital to extend product, hiring, regulatory, deployment, or R&D capacity.

The funding profile suggests budget exists for tools tied directly to de-extinction biotechnology, security, compliance, infrastructure, hiring leverage, and customer deployment. Sellers should map pitches to a funded initiative rather than a generic productivity story.

The best outreach angle is to show how a product shortens deployment time, lowers risk, or improves measurable outcomes for the teams named in the leadership and product sections.